CHENGHUI PHARMACEUTICAL GROUP LTD was founded in June 2002, with a registered capital of 130 million yuan, headquartered in the famous historical and cultural city of Jinan, Shandong Province, which is surrounded by lotus flowers and willows, and a city of mountains and half a city of lakes. It is a high-tech enterprise focusing on the research and development, production, sales and service of pharmaceutical APIs, intermediates and fine chemicals, and is committed to the research and development and application of new technologies in the fields of MAH, CDMO, veterinary medicine and agrochemicals, etc. The Group now has one R&D center, which is located in Jinan, Shandong Province.
The group now has one R&D center-Shandong Chengchuang Blue Ocean Pharmaceutical Technology Co., Ltd, one API factory-Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. and two pharmaceutical intermediates production bases, with more than 1,000 employees, and more than 300 R&D team members.
Business Scope
The company develops and manufactures a wide range of products including local anesthetics, antiviral drugs, cardiovascular and cerebrovascular drugs, antitumor drugs, digestive drugs, hypoglycemic drugs, veterinary drugs and so on. Especially in the "perioperative and antiviral" API research and production, is in a leading position, has formed a competitive advantage of the product structure, products are exported to more than 70 countries and regions around the world.
The company's products Mildronate, Ropivacaine Hydrochloride and Articaine Hydrochloride have been submitted to CEP, of which Mildronate has obtained the CEP certificate; Vonorasan Fumarate, Proamphetamine Hydrochloride, Bupivacaine and Pramoxine Hydrochloride have been submitted to the FDA for the US-DMF documents and obtained the DMF file number; Sugar Glucose Sodium has been passed the audit and certification of MFDS in South Korea; and the Egyptian EDA of Vonorasan Fumarate has been approved and publicized; Domestic registrations have been obtained for 9 APIs, including Lidocaine Hydrochloride, Procaine, Sugar Glucose Sodium and so on.
Main products
Vonorazan Fumarate and intermediates, Dagliflozin and intermediates, Cliborol and intermediates, Letemovir and intermediates, Mildronate, Veterinary products series (intermediates of Floreana, intermediates of Aflana and Sarolana, etc.), Local anesthetic products series (Ropivacaine, Lidocaine, Procainamide, Bupivacaine, etc.), and so on.
MAH Business
Based on the existing APIs, we have carried out in-depth excavation of preparation projects to form a specialized MAH route in niche areas, and have carried out 11 MAH projects, among which the project of Sucralose Sodium has been approved, and the preparation of Lidocaine has been submitted to the National Bureau of China to enter into the stage of clinical research.
CDMO Business
We can undertake high-end pharmaceutical intermediates, new agrochemical intermediates, pet drugs and other veterinary intermediates, big health cross-border products and intermediates customization and services.
With science and technology innovation as the engine and green sustainable development as the concept, we will continue to expand the international market and actively fulfill our social responsibility, dedicated to providing the world with high-quality health products, realizing the goal of sustainable development, and making greater contributions to the cause of human health!
